About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Lilly boosts obesity portfolio with Versanis Bio acquisition

Podcast 14 Jul 2023

Beyond Biotech podcast 54

Life saved: AI discovers existing drug works for rare disease

TME Pharma provides positive glioblastoma trial results

BioGeneration Ventures closes BGV Fund V at €150M 

Calliditas reveals ‘encouraging results’ from head and neck cancer trial 

ADVERTISEMENT

Partnership to progress neurodegenerative disorder treatments

Gene therapy company EG 427 raises €18M

New venture capital company Biovance Capital Partners launches

ADC Therapeutics pauses clinical trial following patient deaths

Pfizer kicks $25M into CellCentric 

Crossbow Therapeutics launches with $80M to target cancer

ADVERTISEMENT